Scribe Therapeutics focuses on creating therapies that permanently treat the underlying cause of disease.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/31/2021 | Series B | $100.45MM | $xx.xx | $300.86MM | Andreessen Horowitz, Avoro Capital Advisors, Avoro Ventures, Menlo Venture, Orbimed Advisors, Perceptive Advisors, Ra Capital Management, T. Rowe, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
16,600,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Avoro Capital Advisors, Avoro Ventures, Menlo Venture, Orbimed Advisors, Perceptive Advisors, Ra Capital Management, T. Rowe, Wellington Management
|
||||||
10/06/2020 | Series A | $20MM | $xx.xx | $51.78MM | Andreessen Horowitz | |
Price per Share
$xx.xx
Shares Outstanding
12,150,003
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz
|
||||||
06/30/2017 | Series A-1 | $205,401.00 | $xx.xx | $2.61MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
155,977
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/30/2017 | Series A-2 | $500,000.00 | $xx.xx | $2.61MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
276,138
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|